This is the login page for PHARMA JAPAN WEB subscribers. PHARMA JAPAN WEB offers excerpts of some articles for free, but paid subscription is required to read full articles.

Today's Headlines RSS

ORGANIZATION

JPMA President Opposes Annual NHI Price Revision

Masayo Tada, president of the Japanese Pharmaceutical Manufacturers Association (JPMA), voiced strong opposition to an annual revision of NHI drug prices on November 20, saying that the current biennial revision ... > Read full story
REGULATORY
MHLW Issues Notification on Infection Risk Reporting for Regenerative Medicines (Nov.21)
REGULATORY
Potential Risk of Narcolepsy for Belsomra Should Be Thoroughly Communicated: Chuikyo (Nov.21)
BUSINESS
Top Two Japan Universities to Offer Undergrads Amgen-Sponsored Lab Experience Programs (Nov.21)
BUSINESS
Domestic Subgroup Analysis Confirms Efficacy of Cimzia: Astellas, UCB Japan (Nov.21)
BUSINESS
Kissei Files NDA for Hyperphosphatemia Treatment in Japan (Nov.21)
> More Latest News

Photosmore

  
Potential Risk of Narcolepsy for Belsomra Should Be Thoroughly Communicated: Chuikyo (Nov.21)Top Two Japan Universities to Offer Undergrads Amgen-Sponsored Lab Experience Programs (Nov.21)PhRMA Chair Prods Japan to Permanently Install Key Pricing Premium (Nov.20)
  
Ihoken Proposes Revision of Compensation Guidelines to Include Compensation for Injury Due to Anticancer Drugs (Nov.20)Health Ministry Drug Evaluation Head Calls for Mulling Necessity of PI Studies for Japanese Patients (Nov.18)Only Advantage of Authorized Generics is that “They Can Be Sold Earlier”: Prof. Ogata (Nov.18)

News Categories

REGULATORY
   MHLW Issues Notification on Infection Risk Reporting for Regenerative Medicines(Nov.21)
   Potential Risk of Narcolepsy for Belsomra Should Be Thoroughly Communicated: Chuikyo(Nov.21)
   Don’t Use Long-Listed Drugs, Dispense Generics: LDP Project Team(Nov.21)
BUSINESS
   Top Two Japan Universities to Offer Undergrads Amgen-Sponsored Lab Experience Programs(Nov.21)
   Domestic Subgroup Analysis Confirms Efficacy of Cimzia: Astellas, UCB Japan(Nov.21)
   Kissei Files NDA for Hyperphosphatemia Treatment in Japan(Nov.21)
ORGANIZATION
   JPMA President Opposes Annual NHI Price Revision(Nov.21)
   PhRMA Chair Prods Japan to Permanently Install Key Pricing Premium(Nov.20)
   Ihoken Proposes Revision of Compensation Guidelines to Include Compensation for Injury Due to Anticancer Drugs(Nov.20)
ACADEMIA
   J-CLEAR’s Kuwajima Criticizes Plan to Legally Regulate Clinical Research(Nov.12)
   ICH-GCP Compliance Obligatory for Clinical Studies Conducted by Chiba University(Oct.28)
   Chiba University Issues Warning to Prof. Involved in VART Study(Oct.28)

Commentary

Was Weak Yen a Plus for April-Sept. Earnings? Profits Partly Canceled Out by Higher R&D, Import Costs

Lexicon

PMDA-WEST:
医薬品医療機器総合機構関西支部

The Column

3 Reasons Why KOL Management Is No Longer Enough

Archives

Don’t Use Long-Listed Drugs, Dispense Generics: LDP Project Team(Nov.21)
Bayer Sets Target of 30% Growth in Group Sales in Japan within 4 Years; Success to Depend Largely on 2 Core Products(Nov.21)
PhRMA Chair Prods Japan to Permanently Install Key Pricing Premium(Nov.20)
CareNet Teams Up with Indian Firm on Marketing Solutions for Drug Makers(Nov.20)
Chuikyo OKs NHI Price Listing of 14 APIs/15 Products(Nov.20)

Most Read

1.
CareNet Teams U...
1.
PAFSC 2nd Commi...
3.
3 Straight Year...
4.
MHLW Official S...
5.
Top Two Japan U...

News Calendar